Compare Quest Diagnostics Inc (DGX) vs e l f Beauty Inc (ELF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs e l f Beauty Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while e l f Beauty Inc trades at $72.75 (market cap $4.26B). The key difference: Quest Diagnostics Inc is far larger — about 5.4× e l f Beauty Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.
| DGX | ELF | |
|---|---|---|
Market Cap | $22.80B | $4.26B |
Sector | Health | Technology |
52-Week High | $216.02 | $146.67 |
52-Week Low | $166.42 | $49.57 |
Enterprise Value | $28.82B | $4.89B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
ELF Beauty trades at $75.10, down 2.15% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.31 billion in 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights brand expansion and a 32% stock jump in June 2026, though growth is transitioning as the core brand softens.
The outlook is mixed: analyst consensus is evenly split between Buy and Hold, with a $74.42 price target near the current price. Upside potential exists from skincare and international expansion, but risks include cost pressures, tariff exposure, and the need to sustain double-digit sales growth amid competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →
